Ascendis Pharma A/S announced that results from VISEN Pharmaceuticals' Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharma's earlier multi-national Phase 3 trial. VISEN Pharmaceuticals' Phase 3 trial achieved its primary endpoint, with pediatric GHD patients treated with once-weekly TransCon hGH demonstrating greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone. In both Ascendis Pharma's and VISEN Pharmaceuticals' Phase 3 trials, TransCon hGH now approved in both the U.S. and EU as a once-weekly treatment for pediatric GHD demonstrated statistical non-inferiority and superiority on the primary endpoint with comparable safety and tolerability to daily growth hormone.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
144.8 USD | +1.92% | +2.35% | +14.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.99% | 8.27B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.29% | 22.19B | |
-16.16% | 21.33B | |
-7.80% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent